ClinicalTrials.gg
RecruitingNCT07228624Updated Oct 19, 2026

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

A Phase 2 interventional study of Ruxolitinib and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 19, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Myelodysplastic-Myeloproliferative Diseases by Fred Hutchinson Cancer Center — 1 open to participants now, 2 under way, none of them phase 3. Myelodysplastic-Myeloproliferative Diseases · Fred Hutchinson Cancer Center.

Planned enrollment
6th of 17
50 · median 36
Started
2026
the only one that year
Phase 2
12 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Myelodysplastic-Myeloproliferative Diseases by Fred Hutchinson Cancer Center, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 12 in phase 2, and was the 22nd registered.

Myelodysplastic-Myeloproliferative Diseases

200 studies on the registry are indexed under Myelodysplastic-Myeloproliferative Diseases; 21 are open to participants now.

Browse Myelodysplastic-Myeloproliferative Diseases studies →

Open to participants now

1 of the 22 studies in Myelodysplastic-Myeloproliferative Diseases by Fred Hutchinson Cancer Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 19 Myelodysplastic-Myeloproliferative Diseases studies recruiting now, 14 (74%) set no upper age limit and 2 (11%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Myelodysplastic-Myeloproliferative Diseases by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial tests the effect of adding ruxolitinib to standard graft versus host disease (GVHD) prevention in treating older patients with myelofibrosis (MF) or myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes before, during, and after a donor (allogeneic) hematopoietic cell transplant (HCT). Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. Giving chemotherapy, such as cytoxan and busulfan or fludarabine and melphalan, before a donor transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving standard prevention (prophylaxis) therapies, such as tacrolimus and methotrexate, after the transplant may stop this from happening. Methotrexate, a type of antifolate, is in a class of medications called antimetabolites. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Tacrolimus is used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Ruxolitinib, a type of Janus-associated kinase (JAK) inhibitor, blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body's immune response and prevent the development of GVHD. Giving ruxolitinib before, during and after allogeneic HCT in addition to standard GVHD prophylaxis may be safe, tolerable and effective in preventing GVHD and improving outcomes in older patients with MF or MDS/MPN overlap syndrome.

Read the detailed description

OUTLINE:

PART 1: Patients receive ruxolitinib or an alternate JAK-inhibitor for at least 8 weeks prior to the start of HCT conditioning. Starting on day -4, patients receive 5 mg of ruxolitinib orally (PO) or via nasogastric tube twice daily (BID) for 12 months then PO via nasogastric tube once daily (QD) until 18 months. Patients receive high intensity conditioning with cyclophosphamide intravenously (IV) on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2 or reduced intensity conditioning with fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 15-30 minutes on days -3 and -2.

PART 2: Patients receive stem cells infusion on day 0. Starting on day -3, patients receive tacrolimus IV over 1-2 hours or PO every 12 hours for at least 100 days. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Additionally, patients undergo urine sample collection, echocardiography (ECHO), chest computed tomography (CT) and pulmonary function testing prior to conditioning and blood sample collection throughout the study. Patients may also undergo bone marrow biopsy and aspiration, and/or spleen ultrasound or CT at multiple time points before and after transplant.

After completion of study treatment, patients are followed at days 28, 100, 180, and at 9 months, 1 year, 18 months and 2 years.

03

Conditions studied

  • Myelodysplastic/Myeloproliferative Neoplasm
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART 1 JAK INHIBITOR ADMINISTRATION: Age 18-75 years

    • Patients > 75 must be considered an HCT candidate, meet all protocol criteria and have comorbidity score =\< 3 and performance status (KPS) > or = to 90. Patients. > 75 who do not meet these criteria may be presented at PCC for consensus exception
  • PART 1 JAK INHIBITOR ADMINISTRATION: Disease criteria

    • Diagnosis of primary or secondary MF as defined by the 2022 World Health Organization classification system or the International Consensus Classification for Myeloid and Acute Leukemias
    • Diagnosis of an MDS/MPN overlap syndrome as defined by the 2022 World Health Organization
  • PART 1 JAK INHIBITOR ADMINISTRATION: Ability to understand and the willingness to sign a written document
  • PART 1 JAK INHIBITOR ADMINISTRATION: Patient must be a potential HCT candidate as assessed by the consenting physician
  • PART 1 JAK INHIBITOR ADMINISTRATION: Patient must be agreeable to taking a JAK-inhibitor (ruxolitinib preferred) for at least 8 consecutive weeks immediately prior to conditioning and be willing to take ruxolitinib 5mg BID starting from day -4 prior to and continuing until 12 months post-transplant as tolerated followed by a 6-month taper.
  • PART 2 STEM CELL TRANSPLANT: Meeting criteria for Part 1 at time of initiation of JAK-inhibitor, including the ability to understand and willingness to sign a written informed consent. Patients arriving to our institution for HCT and not enrolled in Part 1 may still be enrolled in Part 2 if Part 1 criteria are met. These patients will have Part 1 endpoints transcribed from their medical records
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Received a JAK-inhibitor for at least 8 weeks immediately prior to conditioning and be willing to take Rux from day -4 at the 5mg BID dose until 12 months post-transplant as tolerated followed by a 6 month taper
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Performance status score

    • Karnofsky ≥ 70 or > 90 for patients > 75 years old
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: HCT-CI Score \< 8; if patient is > 75 years old HCT-CI \< 3
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Calculated using the Cockcroft-Gault formula or 24-hour urine creatinine clearance must be > 60 ml/min
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Total serum must be \< 3mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Transaminases must be \< 3 x the
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the , ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3mg/dL, and symptomatic biliary disease will be excluded
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Diffusion capacity of lung for carbon monoxide (DLCO) corrected > 60% normal. Patient may not be on oxygen
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: > 40%
  • DONOR: Human leukocyte antigen (HLA)-matched sibling donor
  • DONOR: 10 of 10 HLA-matched unrelated donor
  • DONOR: 9 of 10 allele or antigen mismatched unrelated donor
  • DONOR: Peripheral blood is preferred over bone marrow
  • DONOR: ABO matched donors should be selected if possible
  • DONOR: Matched unrelated donors may be preferred over siblings if the unrelated donor is \< 30 years and the sibling is > 60 years. However, sibling donors \< 70 should be preferred over mismatched unrelated donors

Exclusion criteria

Exclusion Criteria:

  • PART 1 JAK INHIBITOR ADMINISTRATION: to receiving ruxolitinib including patients who have known to JAK inhibitors and
  • PART 1 JAK INHIBITOR ADMINISTRATION: History of prior transplant
  • PART 1 JAK INHIBITOR ADMINISTRATION: Leukemic transformation (> 20% blasts)
  • PART 1 JAK INHIBITOR ADMINISTRATION: Uncontrolled viral, bacterial, or fungal infection despite being on therapy
  • PART 1 JAK INHIBITOR ADMINISTRATION: History of infection
  • PART 1 JAK INHIBITOR ADMINISTRATION: History of untreated tuberculosis (TB)
  • PART 1 JAK INHIBITOR ADMINISTRATION: Pregnant or breastfeeding
  • PART 1 JAK INHIBITOR ADMINISTRATION: Patients with history of myocardial infarction (MI), cerebrovascular accident (CVA) or unprovoked pulmonary embolism (PE)/deep vein thrombosis (DVT) in the past 6 months
  • PART 1 JAK INHIBITOR ADMINISTRATION: Secondary in last 5 years with > 20% risk of relapse
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Contraindication to receiving ruxolitinib including patients who have known hypersensitivity to JAK inhibitors and excipients
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of prior allogeneic transplant
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Leukemic transformation (> 20% blasts)
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Uncontrolled viral or bacterial infection at the time of transplant data review and consent conference
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of HIV infection
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of untreated TB
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Requiring supplemental oxygen
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Pregnant or breastfeeding
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Secondary malignancy in last 5 years with > 20% risk of relapse
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients with a history of MI, CVA, or unprovoked PE/DVT in the past 6 months
  • PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients without an HLA-identical sibling donor, 10 of 10 HLA-matched or 9 of 10 mismatched unrelated donor
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment (ruxolitinib)

    PART 1: Patients receive ruxolitinib or alternate JAK-inhibitor for at least 8 weeks prior to the start of HCT conditioning. Starting on day -4, patients receive ruxolitinib 5mg PO or via nasogastric tube BID for 12 months then PO via nasogastric tube QD until 18 months. Patients receive high intensity conditioning with cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2 or reduced intensity conditioning with fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 15-30 minutes on days -3 and -2. PART 2: Patients receive stem cells infusion on day 0. Starting on day -3, patients receive tacrolimus IV over 1-2 hours or PO every 12 hours for at least 100 days. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

    Drug: Ruxolitinib · Procedure: Allogeneic Hematopoietic Stem Cell Transplantation · Drug: Busulfan · Procedure: Computed Tomography · Drug: Cyclophosphamide · Procedure: Echocardiography Test · Drug: Fludarabine · Drug: JAK Inhibitor · Drug: Melphalan · Drug: Methotrexate · Drug: Tacrolimus · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy

Interventions

  • Given PO or via nasogastric tube

    Also known as: INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424

  • ProcedureAllogeneic Hematopoietic Stem Cell Transplantation

    Given infusion

    Also known as: Allogeneic Hematopoietic Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic

  • Given IV

    Also known as: 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719

  • ProcedureEchocardiography Test

    Undergo echocardiography

    Also known as: EC, Echocardiography

  • Given IV

    Also known as: Fluradosa

  • DrugJAK inhibitorsStudies of JAK inhibitorsJAK inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given JAK inhibitor

    Also known as: JAK inhibitors, Janus Kinase Inhibitor

  • Given IV

    Also known as: Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813

  • Given IV

    Also known as: Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039

  • Given IV or PO

    Also known as: FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius

  • ProcedureBiospecimen Collection

    Undergo urine and blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow biopsy and aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy and aspiration

    Also known as: Biopsy of Bone Marrow

06

What researchers measure

Primary outcomes

  1. Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppression

    Will be estimated as a simple proportion, and the upper bound of the one-sided 95% confidence interval for the estimated proportion will be estimated using the Clopper-Pearson method. The exact binomial test will be used to compare the observed probability to the benchmark of 65%.

    Time frame: Up to day-100

Secondary outcomes

  1. Incidence of grade III-IV acute GVHD

    Will be estimated as simple proportions and informally compared to the results from the historical cohort.

    Time frame: Up to day-100

  2. Incidence of any-grade chronic GVHD

    Will be treated as time-to-event endpoints, with specified point estimates.

    Time frame: Up to 1 and 2 years

  3. Incidence of moderate-to-severe chronic GVHD

    Will be treated as time-to-event endpoints, with specified point estimates.

    Time frame: Up to 1 and 2 years

  4. Non-relapse mortality (NRM)

    Will be estimated as simple proportions and informally compared to the results from the historical cohort.

    Time frame: At day-100

  5. NRM

    Will be treated as time-to-event endpoints, with specified point estimates.

    Time frame: At 1 year

  6. Remission status

    Will be estimated as simple proportions and informally compared to the results from the historical cohort.

    Time frame: At day-100

  7. Relapse rate

    Will be treated as time-to-event endpoints, with specified point estimates.

    Time frame: At 1 and 2 years

  8. Overall survival

    Will be treated as time-to-event endpoints, with specified point estimates.

    Time frame: Up to 1 year and by end of study, assessed up to 2 years

  9. Incidence of graft failure

    Will be estimated as simple proportions and informally compared to the results from the historical cohort.

    Time frame: Up to day-100

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2030, 54 months after the start.

Of 20 phase 2 interventional studies under Myelodysplastic-Myeloproliferative Diseases, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 141. This study's planned 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedDONOR: ABO matched donors should be selected if possible
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedDONOR: ABO matched donors should be selected if possible
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228624
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Feb 4, 2026
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Rachel Salit, MD
Contact
rsalit@fredhutch.org
206-667-1317
Rachel Salit, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion